Skip to page content
Official US Government Icon

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure Site Icon

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

The latest general information on the Coronavirus (COVID-19) is available on Coronavirus.gov. For FAA-specific COVID-19 resources, please visit faa.gov/coronavirus.
United States Department of TransportationUnited States Department of Transportation

Guide for Aviation Medical Examiners

Special Issuances
AME Assisted - All Classes - Chronic Lymphocytic Leukemia

AME Assisted Special Issuance (AASI) is a process that provides Examiners the ability to re-issue an airman medical certificate under the provisions of an Authorization for Special Issuance of a Medical Certificate (Authorization) to an applicant who has a medical condition that is disqualifying under Title 14 of the Code of Federal Regulations (14 CFR) part 67.

An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR � 67.401. The Authorization letter is accompanied by attachments that specify the information that treating physician(s) must provide for the re-issuance determination.

If this is a first-time application for an AASI for the above disease/condition, and the applicant has all the requisite medical information necessary for a determination, the Examiner must defer and submit all of the documentation to the AMCD or RFS for the initial determination.

Examiners may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:

  • An Authorization granted by the FAA;
  • A clinical followup report from the treating physician that includes an update of the condition of the applicant since the last examination; and
  • The results of any applicable laboratory results, including a complete blood count performed within the last 90 days.

The Examiner must defer to the AMCD or Region if:

  • The condition currently requires treatment with a chemotherapeutic agent; or
  • The white blood cell count has risen above 80,000; or
  • Any new treatment is initiated.

Page last modified: